SCM
ATRS

Segantii Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Segantii Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-189,200
Closed -$537K – 309
2017
Q1 		$537K Buy
189,200
+160,200
+552% +$385K 0.09% 81
2016
Q4 		$66K Buy
+29,000
New +$55.2K 0.02% 70

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Segantii Capital Management's ATRS Position: Q2 2017 in Review

Segantii Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2017, closing a stake of 189,200 shares — an estimated $537K sold.

Segantii Capital Management first reported a position in ATRS in Q4 2016 and held it in 2 quarters. The position peaked at $537K in Q1 2017. 103 funds tracked by Wall St. Rank hold ATRS as of Q2 2017.

  • Segantii Capital Management reported no remaining Antares Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 189,200 Antares Pharma, Inc. shares in Q2 2017, an estimated $537K.
  • Segantii Capital Management first reported a position in Antares Pharma, Inc. in Q4 2016 and held it in 2 quarters.
  • Segantii Capital Management's Antares Pharma, Inc. position peaked at $537K in Q1 2017.
  • 103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.